Table of Contents
GAITHERSBURG, Md. – Novavax, Inc. announced that doses of the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) to prevent COVID-19 in individuals aged 12 and older are in stock at major pharmacy retailers across the U.S.
Through agreements with pharmacies, Novavax's updated vaccine is expected to be widely available in locations including, but not limited to, CVS Pharmacy, Rite Aid, Walgreens, Costco, Publix, Sam's Club, Kroger, Meijer, hundreds of other regional grocers and thousands of independent pharmacies. Novavax's updated vaccine received Emergency Use Authorization (EUA) on August 30, 2024 from the U.S. Food and Drug Administration (FDA).
"We have worked hard to ensure greater ease of access for consumers this vaccination season by more than doubling the number of locations stocking our vaccine compared to last year and offering a more convenient presentation in a pre-filled syringe," said John C. Jacobs, President and Chief Executive Officer, Novavax. "Our vaccine targets JN.1, the 'parent strain' of those currently circulating, and our vaccine has demonstrated cross-reactivity against JN.1 lineage viruses, including KP.2.3, KP.3, KP.3.1.1 and LB.1.^1
Novavax's vaccine is the only protein-based option available in the U.S. this fall and is in pre-filled syringe presentation. Doses of Novavax's vaccine can be located on us.novavaxcovidvaccine.com.
